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Abstract
Early mortality (EM; death6 months from diagnosis) has been reported in several newly diag-
nosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was
10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and
cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prog-
nostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors,
are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients
treated with novel agents in the Connect MM® Registry and identified risk factors of the EM
cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and
multivariate analyses were conducted to evaluate associations between baseline characteristics
and EM. Prediction matrices for EM were constructed from a logistic model. Between September
2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow-
up. Of these patients, 102 (6.8%) had EM and 1391 (93.2%) survived for>180 days. Baseline fac-
tors significantly associated with increased EM risk included age>75 years, higher Eastern
Cooperative Oncology Group performance status, lower EQ-5D mobility score, higher ISS stage,
lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM
risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction
matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Iden-
tifying patients at risk for EM may provide new opportunities to implement patient-specific
treatment strategies to improve outcomes.
1 | INTRODUCTION
Even as the new era of multiple myeloma (MM) treatment has gone
beyond novel agents to include aggressive incorporation of stem cell
transplant and monoclonal antibodies, early mortality (EM) remains a
major clinical issue that physicians need to be able to recognize the risk
for and to prevent among their patients with newly diagnosed MM
(NDMM). EM in NDMM is often described within the literature as
death that occurs 2 to 12 months after diagnosis.1,2 Among patients
with NDMM, EM can be influenced by patient age, comorbidities, PS,
therapy, and disease biology.1–6
Risk factors of EM in patients with MM have been investigated in
several studies, including a study that used data from the IFM 2005–01
phase 3 trial to develop a prognostic index of EM.7 That study con-
structed a prognostic index of early MM progression-related death
within 2 years of treatment initiation based on 3 independent prognos-
tic variables: lactate dehydrogenase levels higher than normal, Interna-
tional Staging System (ISS) stage III, and adverse cytogenetics (t[4;14]
and/or del[17p]).7 However, that index did not allow for differential
weighting of each of the 3 prognostic variables, and its applicability is
limited to transplant-eligible patients (who comprise approximately
........................................................................................................................................................................
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
VC 2017 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
Am J Hematol. 2017;1–9. wileyonlinelibrary.com/journal/ajh | 1
Received: 27 February 2017 | Revised: 5 May 2017 | Accepted: 21 May 2017
DOI: 10.1002/ajh.24796
AJH
40% of patients with NDMM) who would meet the strict eligibility cri-
teria of clinical trials in MM. By contrast, prediction matrix models simi-
lar to those created for cardiovascular disease and rheumatoid
arthritis8,9 can be used to calculate the risk of specific outcomes, such
as mortality, and allow for differential weighting for the various model-
specific risk factors. Identifying patients with an increased risk of EM is
critical for physicians to consider implementing different therapeutic
approaches. Prediction tools that analyze both biological and clinical
features have also been successfully used in several hematologic malig-
nancies to predict EM. In acute myeloid leukemia, age, performance sta-
tus (PS), and intensity of treatment have motivated the development of
novel treatment paradigms.10 In diffuse large B-cell lymphoma, molecu-
lar classification and positron emission tomography scans have intro-
duced earlier decisions in the clinical treatment course to improve
outcomes.11,12
Much of what is currently known about risk factors for EM in
patients with NDMM is based on data from clinical trial populations,
which often differ from unselected patient populations due to exclu-
sion of patients who are older, have comorbidities, are in poorer health,
or are often ineligible for stem cell transplant. An observational registry
offers the unique opportunity to report a broad set of baseline charac-
teristics and treatment outcomes while assessing associations between
NDMM biology, patient characteristics, comorbidities, and treatment
selection with outcomes and overall survival. Thus, the Connect MM
Registry investigators sought to review the registry patient population
to get a comprehensive look at the incidence and factors associated
with EM. The registry included patients independent of selection bias,
age, therapy, PS, and comorbidities, which allowed for a cross-sectional
evaluation of patients with NDMM. Using data from a largely unse-
lected patient population reflective of the heterogeneous patients seen
in routine clinical practice, the registry investigators were able to
develop a prognostic tool to assess the risk of EM that allows for dif-
ferential weighting of risk factors. Here, we describe the construction
of an early mortality prediction matrix (EMPM) in a population that
includes both elderly and non–transplant-eligible patients.
2 | METHODS
The Connect MM REGISTRY is a US-based, multicenter, prospective,
observational, cohort registry study designed to describe patterns of
care in NDMM in clinical practice and to analyze patient outcomes in
correlation with baseline characteristics and treatments. Patients were
enrolled into the registry consecutively per protocol to minimize selec-
tion bias. The study design and patient population have been previously
described.13 Briefly, patients were eligible for enrollment within 2 months
of a symptomatic MM diagnosis if aged18 years, able to provide
signed informed consent, and able to complete patient assessment ques-
tionnaires with no or minimal assistance from caregivers. Each partici-
pant enrolled in the Connect MM Registry signed an informed consent
form. Study sites obtained central or local institutional review board
approval. No exclusion criteria were applied. Treatment was at the dis-
cretion of each physician, and patient data were collected at baseline
and quarterly thereafter using electronic case report forms. Collected
data were reviewed and queries issued for consistency. Patients were
censored at the discontinuation date and the data cutoff date. The Con-
nect MM Registry is registered with ClinicalTrials.gov (NCT01081028).
Univariate and multivariate regression modeling was used to evalu-
ate association of baseline characteristics with survival. Variables were
not preselected and represented an exhaustive set of baseline charac-
teristics. A series of univariate logistic regression models were used to
identify variables significantly associated with mortality180 days
after enrollment. This cutoff to define EM was selected by the Connect
MM Steering Committee based on survival patterns seen in previous
noninterventional studies of MM and allowed for assessment of clinical
care and treatment. 5,6,14–16
Missing data are inherent to registries due to their noninterven-
tional nature. The Connect MM Registry allowed for diagnostic data to
be collected at the discretion of the physician, which resulted in miss-
ing data. Patient referrals from one center to another may have also
resulted in missing data. Variables with<60% missing data were
included. Characteristics with P< .15 in univariate analysis were
entered in order of decreasing significance into a series of multivariate
models. The best multivariate model was selected by considering
whether the added variable was significant at the 0.1 level using the
Wald v2 test with 1 degree of freedom. Multiple imputations, based on
the Markov chain Monte Carlo method under the multivariate normal
model,17 were generated for significant variables with 70% nonmissing
data. The final model parameters were estimated for each imputed
data set, and the results, across the imputed data sets, were combined
using the Rubin method.
Construction of prediction matrices was based on a logistic model
for mortality180 days after enrollment. Internal cross-validation of
the model was performed with bootstrap resampling (100 samples)
from the empirical data, using the Harrell C-index18 to determine the
concordance probability. For the logistic model, the concordance prob-
ability is identical to the area under the receiver operating characteris-
tic curve for the model. A prediction matrix is a summary of an
estimated logistic regression that illustrates the predicted probability of
the modeled outcome at constituent levels of each of the predictors. In
this way, the prediction matrix offers insight into the relative impor-
tance of each covariate and can be used to highlight the differential
impact of predictors at different constituent levels.
External validation of the logistic model was also performed using
data from the phase 3 MM-015 trial, which investigated the safety and
efficacy of lenalidomide in combination with melphalan, and prednisone
in patients aged65 years with NDMM.19 The EQ-5D mobility score,
which was not collected in the MM-015 study, was estimated using
Karnofsky PS (Karnofsky PS scores of50 were mapped to the “con-
fined to bed” mobility item, scores between 60 and 80 were mapped to
“some problem walking about,” and scores of90 were mapped to “no
problem in walking about”). The resulting classification of patients from
MM-015 (0%, 55.9%, and 44.1%, respectively) was similar to that of
patients with nonmissing data in the Connect MM Registry (1.0%,
56.4%, and 42.6%, respectively). Similarly, Eastern Cooperative
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TABLE 1 Baseline characteristics and treatment
Mortality within 180 days
(n 5 102)
Mortality > 180 days or censored
(n 5 1391)
Patient speciﬁc
Median age, years (range) 71.5 (38–91) 66.0 (24–94)
Male, n (%) 53 (52.0) 801 (57.6)
Race, n/N (%)a
White 84/102 (82.4) 1137/1390 (81.8)
Black 11/102 (10.8) 186/1390 (13.4)
Other 7/102 (6.9) 67/1390 (4.8)
Median body mass index, kg/m2 (range) 27.4 (14.7–52.6) 27.8 (13.5–58.7)
ECOG performance status  2, n/N (%)a 32/71 (45.1) 144/982 (14.7)
History of diabetes, n/N (%)a 31/100 (31.0) 247/1368 (18.1)
History of hypertension requiring treatment, n/N (%)a 75/99 (75.8) 771/1354 (56.9)
History of VTE, n/N (%)a 6/88 (6.8) 59/1273 (4.6)
Disease speciﬁc
del(17p) from cytogenetics, n/N (%)a 4/16 (25.0) 16/114 (14.0)
del(17p) from FISH, n/N (%)a 10/29 (34.5) 91/356 (25.6)
t(4;14) from FISH, n/N (%)a 3/24 (12.5) 53/297 (17.8)
History of MGUS, n/N (%)a 10/92 (10.9) 151/1308 (11.5)
History of smoldering myeloma, n/N (%)a 5/92 (5.4) 81/1312 (6.2)
Hyperdiploid, n/N (%)a 7/13 (53.8) 81/127 (63.8)
Lactic acid dehydrogenase > 300 g/dL, n/N (%)a 9/42 (21.4) 103/609 (16.9)
Extramedullary plasmacytoma, n/N (%)a 10/16 (62.5) 59/168 (35.1)
Immunoglobulin G  5 g/dL, n/N (%)a 13/80 (16.3) 196/1116 (17.6)
Albumin  3.5 g/dL, n/N (%)a 60/92 (65.2) 667/1294 (51.5)
ISS stage III (calculated), n/N (%)a,b 52/76 (68.4) 373/1061 (35.2)
Myeloma bone involvement, n/N (%)a 73/101 (72.3) 1070/1389 (77.0)
Hypercalcemia (serum calcium  11.5 mg/dL), n/N (%)a 15/102 (14.7) 94/1382 (6.8)
Renal insuﬃciency (serum creatinine > 2 mg/dL), n/N (%)a 34/102 (33.3) 237/1384 (17.1)
Anemia (hemoglobin < 10 g/dL or > 2 below LLN), n (%) 51 (50.0) 619 (44.5)
Platelet count, n/N (%)a
 150 3 109/L 37/100 (37.0) 291/1388 (21.0)
> 150 3 109/L 63/100 (63.0) 1097/1388 (79.0)
IMWG risk category, n/N (%)a
High risk 19/60 (31.7) 234/875 (26.7)
Standard risk 39/60 (65.0) 553/875 (63.2)
Low risk 2/60 (3.3) 88/875 (10.1)
b2-microglobulin ( 5.5 mg/L), n/N (%)a 52/78 (66.7) 373/1077 (34.6)
HRQOL from EQ-5D, n/N (%)a
Self-care from EQ-5D (unable to wash or dress) 10/98 (10.2) 21/1381 (1.5)
Mobility from EQ-5D (conﬁned to bed) 5/99 (5.1) 10/1384 (0.7)
Treatment
Setting, n (%)
Community 82 (80.4) 1129 (81.2)
Academic 18 (17.6) 245 (17.6)
Government 2 (2.0) 17 (1.2)
Timing, n (%)
 60 days 93 (91.2) 1330 (95.6)
> 60 days 0 (0.0) 27 (1.9)
Treatment not started 9 (8.8) 34 (2.4)
Novel therapy
1, n/N (%)a 72/87 (82.7) 890/1268 (70.2)
 2, n/N (%)a 15/87 (17.2) 378/1268 (29.8)
Combination therapy
Doublet therapy (use of 2 therapies), n/N (%)a 52/93 (56.0) 606/1357 (44.6)
Triplet therapy (use of 3 therapies), n/N (%)a 28/93 (30.0) 607/1357 (44.7)
Unknown, n (%) 9 (8.8) 34 (2.4)
Radiation therapy for myeloma, n/N (%)a 24/98 (24.5) 211/1377 (15.3)
HRQOL indicates health-related quality of life; LLN, lower limit of normal; MGUS, monoclonal gammopathy of undetermined significance; and VTE,
venous thromboembolism.
aN5patients with data available.
bCalculated using albumin and b2-microglobulin levels from diagnosis or if not present from enrollment.
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Oncology Group (ECOG) PS was estimated using conversion criteria for
Karnofsky PS scores recommended by the European Society for Medi-
cal Oncology.20,21 A second external validation was conducted using
data from the phase 3 FIRST (Frontline Investigation of Lenalidomi-
de1Dexamethasone Versus Standard Thalidomide) trial (MM-020),
which investigated the safety and efficacy of lenalidomide plus low-
dose dexamethasone given until disease progression in transplant-
ineligible patients with NDMM.22 Finally, the model was validated uti-
lizing data from a second cohort of patients with10 months of
follow-up (n51492) enrolled in the Connect MM REGISTRY from
December 2012 to April 2016. All 7 variables identified as predictors of
EM in the logistic model developed from the Connect MM Registry
data were collected in the FIRST study. Both external validations used
the same 7 variables identified from the Connect MM data set and
were conducted using the rms package of the R statistical programming
language using the methods of Harrell.18
3 | RESULTS
3.1 | Patients
A total of 1493 protocol-eligible patients were consecutively enrolled in
the registry between September 2009 and December 2011 (Cohort 1)
and had adequate baseline and postbaseline data. At the data cutoff
date of November 30, 2014, the median time of follow-up in the Con-
nect MM Registry was 33.8 months (range, 0–59.8 months). Of the
1493 patients analyzed, 102 (6.8%) had EM (survival of180 days) and
1391 (93.2%) survived for>180 days or were censored. The median
time from diagnosis to enrollment was 25 days. Patient characteristics
between those who enrolled early (< 25 days from diagnosis) vs those
who enrolled later ( 25 from diagnosis) were similar. A logistic regres-
sion analysis indicated that there was no bias in the probability of EM
due to the lag time between diagnosis and enrollment (early vs late
enrollers; odds ratio 1.19; 95% CI: 0.8–1.79; P50.390). Furthermore,
14 patients were hospitalized when they signed or immediately after
they signed the informed consent document, indicating that very sick
patients enrolled into the registry.
3.2 | Baseline characteristics
At baseline, patients with EM were older than patients who survived
for>180 days (median age, 71.5 vs 66.0 years, respectively) and had a
history of more comorbidities, including diabetes (31.0% vs 18.1%) and
hypertension (75.8% vs 56.9%) (Table 1). A greater proportion of
patients with EM had renal insufficiency (33.3% vs 17.1%), hypercalce-
mia (14.7% vs 6.8%), and low platelet counts (37.0% vs 21.0%) as well
as poorer PS (ECOG PS2 in 45.1% vs 14.7%). High-risk disease fea-
tures were more common in patients with EM. These features included
extramedullary disease (62.5% vs 35.1%), low serum albumin levels
(65.2% vs 51.5%), and elevated b2-microglobulin concentrations
( 5.5 mg/L; 66.7% vs 34.6%). A greater proportion of patients with
EM had ISS stage III disease (68.4% vs 35.2%). Similarly, del(17p) by
cytogenetic analysis (25.0% vs 14.0%) and del(17p) by fluorescence in
situ hybridization (FISH) analysis (34.5% vs 25.6%) were more common
in patients with EM than patients who survived for>180 days.
3.3 | Treatment
The majority of patients in both groups (approximately 81%) were
enrolled within community practices, and approximately 18% were
enrolled in academic centers (Table 1). The timing of initiating treat-
ment was similar for both patient groups. A smaller proportion of
patients with EM vs longer-surviving patients received2 novel thera-
pies (17.2% vs 29.8%) and triplet therapy (30.0% vs 44.7%). Radiation
therapy for myeloma was administered to a higher proportion of
patients with EM (24.5% vs 15.3%).
3.4 | Causes of death
For the 102 patients with EM, 39.2% (2.7% of the total enrolled
patients) of deaths were related to MM progression and 32.4% were
related to nonmyeloma causes. Common causes of death in patients
with EM included heart failure, pneumonia, other infection, and renal
failure, and 28.4% were listed as other or unknown causes (Table 2).
For the 1391 patients surviving for>180 days, 31.5% died within the
time frame of this analysis. The majority of these deaths (58.2%) were
directly attributed to myeloma progression and 5% were due to non-
myeloma causes. Common causes of death included renal failure, heart
failure, pneumonia, and other infections; in 25.8% of patients, the
cause of death was listed as other or unknown.
3.5 | Logistic regression analysis
In the univariate analysis, 15 baseline factors were statistically associ-
ated with EM (Table 3). The 15 factors were included in the multivari-
ate logistic regression analysis and following an iterative variable
selection process, 6 variables were identified as significantly associated
with a higher likelihood of EM: age (> 75 years), prior hypertension,
higher ECOG PS, higher ISS stage, lower platelet count, and lower
EQ-5D mobility score (Table 3). Additionally, a trend toward increased
likelihood of EM was associated with renal insufficiency (serum
creatinine>2 mg/dL), making renal insufficiency a seventh factor. The
7 factors identified in the multivariate regression analysis were used
to construct a prediction matrix that estimated the probability of EM
(Figure 1A).
3.6 | Validation
Internal cross-validation of this model found a 2.2% reduction in the
concordance probability in the test bootstrap resampling estimate com-
pared with the training bootstrap estimate. The training optimism-
adjusted concordance probability of the fitted logistic model was esti-
mated as 74.3% (95% CI: 68.7%-80.0%); a concordance probability sig-
nificantly greater than 50% is indicative of a good predictive model.
Consistent with these results, external validation using data from
patients with NDMM enrolled in the MM-015 phase 3 trial resulted in
a concordance probability of 76.7% for the logistic model (Figure 1B).
4 | AJH TEREBELO ET AL.
A second external validation was conducted using data from patients
with NDMM enrolled in the phase 3 FIRST trial, which demonstrated a
concordance probability of 71.8% for the logistic model (Figure 1C).
Validation using data from the 1492 Cohort 2 patients who had
10 months of follow-up resulted in a concordance probability of
71.4% for the logistic model (Figure 1D). Patient characteristics were
similar between Cohort 1 and Cohort 2: median age was 67 years for
both cohorts; 57% and 58% were male, respectively; 28% and 27%
had ISS stage III disease, respectively. A full report on the second
cohort of patients (n51518) enrolled from December 2012 to April
2016 into the Connect MM REGISTRY will be provided at a later date.
4 | DISCUSSION
Before the era of novel agents, the incidence of EM was 10% to 14%
in patients with NDMM.1,5,15,23 Advances in myeloma treatment
(i.e., therapeutic approaches and supportive care) have improved long-
term outcomes and survival. However, despite increasing awareness of
its phenomenon, EM remains an area of unmet medical need and not all
patients benefit from the long-term impact of novel agents. EM was fur-
ther brought to light by the impassioned management issues with newly
diagnosed patients by Gonsalves et al.24 The authors defined the inci-
dence of EM from phase 3 trials and outlined key management strat-
egies for patients with NDMM to help mitigate EM, while also touching
on the patients most at risk for EM. The EMPM described here offers
clinicians the parameters to identify and treat patients with NDMM at
risk for EM and the opportunity to address EM in clinical trials.
The prognosis of NDMM depends on staging, patient features, dis-
ease biology, and treatment outcomes.3 Current tools designed for risk
stratification use the revised ISS (r-ISS) for MM from the International
Myeloma Working Group (IMWG); the r-ISS is important for long-term
prognosis but has not been used to identify patients at risk for EM.25
Because the r-ISS is a point-based system, it is less possible to assess
the relative contribution of each element. In addition, the r-ISS is pre-
dominantly based on disease-specific risk factors and does not account
for patient-specific risk factors. Similar to the r-ISS, the frailty score is a
point-based system that combines age, functional status, and comor-
bidities to predict long-term survival and feasibility of a treatment regi-
men in elderly patients with NDMM.26 Combining the frailty score
with the r-ISS stage improves the prognostic value of each score indi-
vidually to predict long-term survival, but neither score combined or
alone has been used to identify patients at the highest risk for EM.
Prognostic studies have provided physicians with a better under-
standing of the relationship between aggressiveness of disease and
survival in patients with NDMM. However, significant gaps remain in
our understanding of the best methods of stratifying risk in these
patients, incorporating patient- and disease-specific risk factors and the
relative contributions of individual risk factors. The existing point-
based systems make it difficult to accurately predict outcomes in patients
who have a mixture of high- and standard-risk characteristics.14,25–27
Furthermore, the point-based models are primarily based on data from
interventional clinical trials and may not represent the general MM
patient population. Therefore, using data from a patient registry, we set
out to create an EMPM model that allows differential weighting of the
impact of individual patient- and disease-specific risk factors.
Patient comorbidities have been associated with higher mortality in
various clinical trials of patients with MM.4,16,28–34 For some patients
with MM, comorbidities are a direct cause of death, but they also put
patients at risk for early disease-related mortality by compromising the
ability to effectively give treatment.4,28,30,31 Although the 6.8% inci-
dence of EM observed in this study suggests the benefit of novel agents
and improved supportive care, there are several issues to be noted.
Patients in our study with EMwere older and in generally poorer health,
with higher rates of comorbidities (including diabetes and hypertension),
greater burden of disease, and high-risk features such as ISS stage III
and the presence of del(17p) cytogenetics. Consistent with these
TABLE 2 Primary cause of death
Mortality within 180 days
(n5102)
Mortality > 180 days or censored
(n51391)
Total deaths, n 102 438
Directly attributed to myeloma progression, n (%) 40 (39.2) 255 (58.2)
Not directly attributed to myeloma progression, n (%) 33 (32.4) 70 (5.0)
Heart failure, n (%)a 11 (33.3) 17 (24.3)
Other infection, n (%)a 7 (21.2) 12 (17.1)
Pneumonia, n (%)a 6 (18.2) 18 (25.7)
Renal failure, n (%)a 4 (12.1) 19 (27.1)
Sudden death, n (%)a 2 (6.1) 0 (0.0)
Pulmonary embolus, n (%)a 2 (6.1) 1 (1.4)
Vascular event, n (%)a 1 (3.0) 2 (2.8)
Bleeding, n (%)a 0 (0.0) 1 (1.4)
Other, n (%) 20 (19.6)b 65 (14.8)
Unknown, n (%) 9 (8.8) 48 (11.0)
aProportion due to deaths not directly attributed to myeloma progression.
bOther deaths included sepsis (n57), cardiac related (n53), lung and brain cancer (n52), and single occurrences of death due to aspiration pneumoni-
tis, complications from anasarca, emphysema, gastrointestinal hemorrhage, liver failure, multiorgan system failure, perforated diverticulum, and respira-
tory arrest.
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observations, the median time from diagnosis to enrollment was
25 days, indicating that this study did not likely select for a healthy pop-
ulation of patients with MM. In our prediction matrix, lower mobility
score, age>75 years, history of hypertension, lower platelet count,
higher ECOG PS, high ISS disease stage, and renal insufficiency were
associated with a higher likelihood of EM. Although identified as
FIGURE 1 EMPM with estimated probability of mortality within 180 days (A) and external validation model using data from previous trials (B,
C, and D). (A) Green, yellow, and red shading represent lower, intermediate, and higher probabilities of EM, respectively. As an example in the
practical use of the EMPM, consider a patient with NDMM enrolled in the Connect MM Registry. This patient answered “I have some problems
walking about” to the EQ-5D mobility question, and his platelet count was 150 3 109/L. This patient had an ECOG PS of 2, had a history of
hypertension, and was 56 years old. He had ISS stage III disease and a serum creatinine level of 3.19 mg/dL. Entering these baseline factors into
the EMPM showed that this patient had a 57% chance of mortality within the first 180 days on study and, in actuality, the patient died at 26
days. Creat indicates serum creatinine and PC, platelet count. (B) Data from MM-015, (C) data from the FIRST trial, and (D) data from the second
cohort of the Connect MM registry. Triangles represent observations in groups of 30 (groups ordered from most probable to least probable) for
whom the actual probabilities (from the MM-015, FIRST trial, or Cohort 2 data) are plotted against the predicted probabilities (based on the Con-
nect MM logistic model). The solid line and the curved dotted line (nonparametric curve) are the fitted curves for the plot of actual and predicted
probabilities. The C-index or concordance probability is the probability that a randomly selected pair of patients in the independent external data
set, one with a poorer survival outcome than the other, will be correctly differentially identified based on inputting the 2 patients’ baseline prog-
nostic characteristics in the fitted model obtained from the Connect MM Registry.
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significant in the univariate analysis, albumin level, b2-microglobulin
level, degree of anemia, history of diabetes, hypercalcemia, IMWG risk,
del(17p) mutation, and self-care score from EQ-5D were not found to
be independently associated with EM in the multivariate analysis. In
addition, patients with EM required more radiation, which likely limited
their ability to receive more aggressive therapy ( 2 novel therapies or
triplet therapy) or potentially led to a delay in initiating systemic ther-
apy. It is important to note that although a lower proportion of patients
with EM were treated with2 novel therapies, this was not a signifi-
cant factor for EM in the multivariate analysis. Lastly, the current
TABLE 3 Baseline characteristics associated with mortality within 180 days by univariate and multivariate logistic regression analyses
Univariate Analysis
Estimate 95% CI Pa
Patient speciﬁc
Age ( 75 vs>75 years) 2.09 1.37–3.19 .001
Body mass index, kg/m2 1.06 0.84–1.34 .606
ECOG performance status 7.02 3.30–14.9 < .001
History of diabetes 2.04 1.31–3.18 .002
History of hypertension 2.36 1.47–3.79 < .001
History of VTE 1.51 0.63–3.59 .356
Disease speciﬁc
del(17p) from FISH and cytogenetic forms 1.80 0.90–3.57 .095
t(4;14) from FISH 0.87 0.26–2.93 .822
History of MGUS 0.93 0.47–1.84 .845
History of smoldering myeloma 0.87 0.34–2.21 .775
Hyperdiploid 1.53 0.66–3.57 .321
Lactic acid dehydrogenase ( 300 vs > 300 g/dL) 1.34 0.62–2.89 .454
Extramedullary plasmacytoma (yes/no) 1.42 0.81–2.49 .227
Immunoglobulin G class (< 5 g/dL vs  5 g/dL) 0.91 0.49–1.68 .765
Albumin ( 3.5 g/dL vs > 3.5 g/dL)b 1.62 1.06–2.49 .027
ISS disease stage (calculated) 4.00 2.42–6.59 < .001
Myeloma bone involvement 0.78 0.49–1.22 .276
Hypercalcemia (serum calcium  11.5 mg/dL) 2.41 1.34–4.34 .003
Renal insuﬃciency (serum creatinine > 2 mg/dL) 2.45 1.59–3.79 < .001
Anemia (hemoglobin < 10 g/dL or > 2 below LLN) 1.25 0.84–1.88 .269
Platelet count ( 150 3 109/L vs > 150 3 109/L) 2.66 1.77–4.02 < .001
IMWG risk 1.42 0.90–2.23 .133
b2-microglobulin ( 5.5 mg/L)b 2.86 1.91–4.30 < .001
HRQOL from EQ-5D
Self-care from EQ-5D 2.18 1.53–3.09 < .001
Mobility from EQ-5D 3.22 2.04–5.10 < .001
Novel therapy
Novel therapy use (0, 1) vs  2 0.46 0.26–0.81 .007
Multivariate Analysisc
Estimate 95% CI P
Patient speciﬁc
Age ( 75 vs>75 years) 1.70 1.09–2.67 .020
ECOG performance status 3.89 1.67–9.05 .002
History of hypertension 1.96 1.19–3.22 .008
Disease speciﬁc
ISS disease stage (calculated) 1.85 1.18–2.90 .007
Renal insuﬃciency (serum creatinine > 2 mg/dL) 1.59 0.98–2.60 .062
Platelet count ( 150 3 109/L vs > 150 3 109/L) 2.29 1.49–3.53 < .001
HRQOL from EQ-5D
Mobility from EQ-5D 2.42 1.48–3.94 < .001
HRQOL indicates health-related quality of life; LLN, lower limit of normal; MGUS, monoclonal gammopathy of undetermined significance; and VTE,
venous thromboembolism.
aBaseline characteristics with P values in bold were considered significant at P< .15 in the univariate analysis.
bAlbumin and b2-microglobulin levels were analyzed as independent variables separate from ISS stage to understand their individual impact in the final
model.
cBaseline characteristics for which multivariate data are not presented are those that were screened out because either they had univariate P > .15 or
they were not significant in the variable selection step.
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analysis of patients with high-risk disease was limited by too few
patients with conventional cytogenetic and FISH data.13 However, as
the data mature, a future analysis can be conducted to characterize
patients with high-risk disease who did not die within 180 days com-
pared with patients with non–high-risk disease who had a longer sur-
vival time.
The EMPM presented here was developed based on a test cohort
of the first approximately 1500 patients enrolled in the Connect MM
Registry and has been validated by bootstrap resampling for internal
cross-validation. Additionally, a high degree of concordance was
observed when we applied 2 external validations of the model using
data from patients enrolled in the phase 3 MM-015 trial and the phase
3 FIRST trial, despite more restrictive sets of inclusion/exclusion crite-
ria in those studies. Although external validation was one of the
strengths of this study, a potential limitation was the use of well-
controlled phase 3 randomized trials and not a similar, general-patient
population. Therefore, we also applied the model to a second cohort of
patients who enrolled in the Connect MM Registry between December
2012 and April 2016. Despite the difference in enrollment periods
between the first cohort (2009–2011) and the second cohort, which
enrolled during the era of novel agents and a rapidly changing treat-
ment landscape in multiple myeloma, there was a high degree of con-
cordance between predicted and actual probabilities of EM. Future
analyses could also include additional data to distinguish between
comorbidities related to frailty vs advanced disease, which could help
inform management decisions. Thus, with further validation and analy-
ses, the myeloma EMPM has the potential to be a clinically useful tool
not only for physicians to identify patients with NDMMwho are at risk
for EM but also for analyses of specific patient populations, selection
of therapy, identification of new targets for treatment, and standar-
dized comparisons between trials.
There are several inherent limitations to using data from patient
registries. Because data collection is more passive than collection of
interventional trial data, there is an increased likelihood of missing
data.35 If a patient is new to a clinic, complete medical and clinical
history may not be available. Furthermore, data is as reported by the
treating physician and it is often difficult to interpret missing data.36
To reduce data missingness and inaccuracies, we conducted com-
prehensive data review, including issuing queries to sites and con-
ducting limited site monitoring. Registry patients are also treated in
community practices where delivery and choice of care is at physi-
cian discretion. Finally, although generalizability of registry data to a
disease population as a whole is considered a strength, it is depend-
ent on the source population from which the registry enrolls
patients.37
In conclusion, high-quality systematic research to identify
patients at risk for EM have been limited. The EMPM is the first
weight-based model that accounts for both patient- and disease-
specific risk factors. Importantly, our study highlighted common
causes of EM, including cardiac and infectious complications. This
model can facilitate early recognition of patients with high-risk dis-
ease and help physicians introduce personalized treatment, such as
incorporation of early consultation with a cardiologist, avoidance of
nephrotoxic agents, careful monitoring of steroid dosing in patients
with diabetes, prompt and early initiation of doublet or triplet therapy
with limited radiation fields, and the use of prophylactic antibiotics.
This model also supports additional studies in these subsets of
patients to evaluate potential strategies to reduce the risk of EM.
Other strengths of the EMPM are ease of use and the ability to rap-
idly implement into routine clinical practice and consider risk-adapted
approaches to disease management.
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